Factors influencing the efficacy of initial adrenocorticotropic hormone therapy for infantile epileptic spasms syndrome / 中国当代儿科杂志

OBJECTIVES@#To study the factors influencing the short-term (28 days) efficacy of initial adrenocorticotropic hormone (ACTH) therapy for infantile epileptic spasms syndrome (IESS), as well as the factors influencing recurrence and prognosis.@*METHODS@#The clinical data were collected from the children with IESS who received ACTH therapy for the first time in the Department of Pediatric Neurology, Xiangya Hospital of Central South University, from April 2008 to January 2018 and were followed up for ≥2 years. The multivariate logistic regression analysis was used to evaluate the factors influencing the short-term efficacy of ACTH therapy, recurrence, and long-term prognosis.@*RESULTS@#ACTH therapy achieved a control rate of seizures of 55.5% (111/200) on day 28 of treatment. Of the 111 children, 75 (67.6%) had no recurrence of seizures within 12 months of follow-up. The possibility of seizure control on day 28 of ACTH therapy in the children without focal seizures was 2.463 times that in those with focal seizures (P<0.05). The possibility of seizure control on day 28 of ACTH therapy in the children without hypsarrhythmia on electroencephalography on day 14 of ACTH therapy was 2.415 times that in those with hypsarrhythmia (P<0.05). The possibility of recurrence within 12 months after treatment was increased by 11.8% for every 1-month increase in the course of the disease (P<0.05). The possibility of moderate or severe developmental retardation or death in the children without seizure control after 28 days of ACTH therapy was 8.314 times that in those with seizure control (P<0.05). The possibility of moderate or severe developmental retardation or death in the children with structural etiology was 14.448 times that in those with unknown etiology (P<0.05).@*CONCLUSIONS@#Presence or absence of focal seizures and whether hypsarrhythmia disappears after 14 days of treatment can be used as predictors for the short-term efficacy of ACTH therapy, while the course of disease before treatment can be used as the predictor for recurrence after seizure control by ACTH therapy. The prognosis of IESS children is associated with etiology, and early control of seizures after ACTH therapy can improve long-term prognosis.

Vigabatrina comparado con hormona adrenocorticotrópica para el tratamiento de espasmos infantiles y Síndrome de West / Vigabatrin compared with adrenocorticotropic hormone for the treatment of infantile spasms and West Syndrome

OBJETIVO: Determinar los riesgos y beneficios del uso de vigabatrina comparada con hormona adrenocorticotrópica (ACTH) para el tratamiento de espasmos infantiles. MÉTODO: Se realizó una búsqueda en Epistemonikos. Se extrajeron datos desde las revisiones identificadas. Se realizó un metaanálisis a partir de estudios primarios y se utilizó el método GRADE para la presentación de resultados. RESULTADOS: Se identificaron nueve revisiones sistemáticas. Se observó que el uso de vigabatrina en comparación con ACTH disminuye la resolución de espasmos (RR 0,8, IC 95% 0,65 - 0,98) y podría disminuir la resolución de hipsarritmia (RR 0,71, IC 95% 0,48 - 1,05). No fue posible determinar si el uso de vigabatrina disminuye el riesgo de desarrollar efectos adversos (RR 0,75, IC 95% 0,23 - 2,45) por certeza de evidencia muy baja. CONCLUSIONES: La evidencia parece inclinarse a favor del uso de ACTH. Sin embargo debe considerarse la necesidad de nuevas investigaciones para esclarecer su seguridad.

OBJECTIVE: To determine the risks and benefits of the use of vigabatrin compared to ACTH for the treatment of infantile spasms. METHOD: A search in Epistemonikos was performed. Data were extracted from the identified reviews. A meta-analysis was performed from primary studies and the GRADE method was used to present the results. RESULTS: Nine systematic reviews were identified. Vigabatrin use compared to ACTH was found to decrease resolution of spasms (RR 0.8, 95% CI 0.65 - 0.98) and might decrease resolution of hypsarrhythmia (RR 0.71, 95% CI 0 .48 - 1.05). It was not possible to determine whether the use of vigabatrin reduces the risk of developing adverse effects (RR 0.75, 95% CI 0.23 - 2.45) due to very low certainty of evidence. CONCLUSIONS: The evidence seems to lean in favor of the use of ACTH. However, the need for new research should be considered to clarify its safety.

Síndrome transicional: del síndrome de West al síndrome de Lennox-Gastaut / Transional syndrome: from West to Lennox-Gastaut syndromes

El síndrome de West o espasmos infantiles, es una encefalopatía epiléptica clasificada como epilepsias y síndromes generalizados. Hay múltiples informes de la evolución de síndrome de West a síndrome de Lennox-Gastaut de un 25 hasta 60%, sin reconocerse una causa específica. Se ha comunicado que pueden ser solo una entidad epiléptica dependiente de la edad y que estaría en relación con el grado de inmadurez cerebral. En esta revisión retrospectiva de 130 casos de espasmos infantiles, solo 14 (10.7%) evolucionaron a Lennox-Gastaut. El haber recibido en todos los casos vigabatrina como tratamiento nos hace suponer que la baja incidencia podría estar relacionada con el uso de este fármaco. Dado que la vigabatrina tiene una acción gabaérgica y aumenta los niveles de ACTH podría explicar esta relación, pero esto deberá confirmarse con el mejor conocimiento de los mecanismos íntimos de estas graves encefalopatías.

West syndrome or infantile spasms is an epileptic encephalopathy, classified as generalized epilepsies and syndromes. There are multiple reports of the evolution from West to Lennox-Gastaut syndrome of 25 up to 60%, without a specific cause is determined. It has been reported that they may be only an epileptic entity age dependent that it would be in relation to the degree of brain immaturity. In this retrospective review of 130 cases of West syndrome, only 14 (10.7%) evolved to Lennox-Gastaut. Having received in all cases vigabatrin as a treatment, makes us suppose that the low incidence could be related to the use of this drug. Given that vigabatrin has a gabaergic action and increased levels of ACTH, may explain this relationship but this must be confirmed with the best knowledge of the intimate mechanisms of these serious epileptic encephalopathies.

efficacy and safety of zonisamide as an add-on drug in the treatment of Lennox-Gastaut syndrome

The Lennox-Gastaut syndrome [LGS: the triad of intractable seizures of various types, a slow spike-wave pattern in EEG and mental retardation] is one of the most difficult epilepsy syndromes to treat. The aim of this study was to evaluate the efficacy and safety of zonisamide [ZNS] as add-on therapy in seizures of children with LGS. In a quasi-experimental study, seizure frequency and side effects of 40 children with LGS who were referred to the pediatric neurology clinic of Shaheed Sadoughi University of Medical Sciences, Yazd, Iran, between September 2008 and November 2009 and were on ZNS for six months were evaluated. Twenty one boys and 19 girls with a mean age of 6.6 +/- 3.6 years were evaluated. At the end of six months of treatment with ZNS, 25% became seizure free, 25% had >50% reduction in seizure frequency while 35% did not have a notable change in seizure frequency and 15% experienced an increase in seizure frequency. Drug was effective in 62.5% of the myoclonic and generalized tonic-clonic, 50% of the atonic, 43% of the mixed type and 33.4% of the tonic seizures. Transient side effects were seen in 25% of the patients: drowsiness in 10%, hyperthermia in 5% and irritability, fatigue, ataxia and anorexia [each one] in 2.5% of the patients. No serious side effects were reported. ZNS could be considered as an add-on therapy in the management of intractable epilepsy in LGS

Seizure characteristics in Aicardi syndrome

We are describing a one year old Bahraini girl with Aicardi syndrome; she has agenesis of the corpus callosum, inter hemispheric cyst, neuronal migration disorder, ocular abnormalities and infantile spasm. She presented initially with focal seizure which later evolved into infantile spasm, her seizures were intractable to different anticonvulsant medications except for Vigabatrin which reduced her seizure episodes dramatically

Presentación de un caso de aplicación de la dieta cetogénica en la epilepsia refractaria / Presentation of a case of application of the diet cetogénica in the fireproof epilepsy

Se presenta el caso de un paciente del sexo masculino, de 2 años de edad, que padece síndrome de West y que ha recibido tratamiento con múltiples drogas antiepilépticas sin obtener resultados alentadores ni en las crisis ni en su desarrollo psicomotor, seriamente afectado. Se establece el régimen de alimentación cetogénico de instalación progresiva, sin período de ayuno inicial, y se observa un cambio clínico en el paciente a partir de que se logran niveles de cetosis, constatados por la aparición de cuerpos cetónicos en la orina. Los cambios clínicos consisten en la disminución del número de crisis diarias y de su intensidad, en la posibilidad de suspender una de las drogas antiepilépticas que usaba, y en el aumento del nivel de vigilia del paciente. Se concluye que no se debe renunciar a esta alternativa de tratamiento en los casos de epilepsia refractaria.

The case of a 2-year-old male patient suffering from West syndrome that had been treated with multiple antiepileptic drugs without encouraging results, neither in the seizures, nor in his psychomotor development, which was seriously affected, was reported. A progressive ketogenic diet was established without initial fasting, and it was observed a clinical change in the patient, since ketosis levels were attained and confirmed by the appearance of ketone bodies in urine. The clinical changes consisted in the reduction of the number of daily seizures and their intensity, in the possibility of stopping the use of one of the antiepileptic drugs, and in the increase of the level of sleeplessness of the patient. It was concluded that this treatment alternative should not be rejected in the cases of refractory epilepsy.

Treatment of infantile spasms with sodium valproate followed by benzodiazepines.

OBJECTIVE: To review the result of the infantile spasms' treatment with sodium valproate followed by nitrazepam or clonazepam. STUDY DESIGN: Descriptive retrospective study. SETTING: Srinagarind Hospital, Department of Pediatrics, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand. MATERIAL AND METHOD: Twenty-four infantile spasms admitted between January 1994 and December 2003 were analyzed. The inclusion criteria were the patients with infantile spasms clinically diagnosed by the pediatric neurologist, having hypsarrhythmic pattern EEG, and receiving sodium valproate with or without nitrazepam or clonazepam. The patients who had an uncertain diagnosis, incomplete medical record, or that were incompletely followed up were excluded. Data were collected on sex, age at onset of seizure, type of infantile spasms, associated type of seizure, predisposing etiological factor, neuroimaging study, and the result of treatment including cessation of spasms, subsequent development of other seizure types, quantitative reduction of spasms, relapse rates of spasms, psychomotor development, and adverse effects of AEDs. RESULTS: The mean age at onset was 177 days. The male-to-female ratio was 1:1.2. There were 13 cryptogenic (54.2%) and 11 symptomatic (45.8%) infantile spasms. The most common predisposing etiological factors in symptomatic cases were hypoxic ischemic encephalopathy (45.5%) and microcephaly (36.4%), respectively. Ten patients received sodium valproate (41.7%), another 10 received sodium valproate with clonazepam (41.7%), and four received sodium valproate with nitrazepam (16.7%). Both, the complete cessation rate and the 50% reduction of spasms rate were 45.8%. The duration to complete cessation was 70 days. The relapse rate was 18.2%. The rate of delayed psychomotor development was 83.3%. The mean duration of follow-up was 49.6 months. CONCLUSION: The authors propose to use sodium valproate concomitantly with benzodiazepines, especially clonazepam, in situations such as unavailability, intolerability, or adverse effects of ACTH or vigabatrin, or in a patient who does not respond to ACTH or vigabatrin.

Vigabatrina no tratamento da síndrome de West: avaliação clínica e eletrencefalográfica em 13 pacientes / Treatment of West syndrome with vigabatrin: clinical and electroencephalographic evaluation of 13 patients

Avaliamos a eficácia da vigabatrina (VGB) como monoterapia inicial para síndrome de West (SW), os seus efeitos colaterais e a evolução a curto prazo do eletrencefalograma (EEG), num estudo prospectivo, aberto e não controlado. A amostra foi de 13 lactentes atendidos entre outubro/2001 a setembro/2002 no ambulatório do IMIP ou em clínica privada. A dose média utilizada da VGB foi 118 mg/kg/dia. Houve supressão dos espasmos em 4 crianças (31 por cento), controle parcial em 3 (23 por cento), ausência de resposta em 5 (38 por cento) e piora em 1 (8 por cento). Dos 2 pacientes portadores de esclerose tuberosa, um ficou livre dos espasmos e o outro teve controle parcial. Efeitos colaterais ocorreram em 8 crianças (62 por cento) e consistiram de irritabilidade, insônia, sonolência e agitação, sendo todos toleráveis. Ocorreu desaparecimento da hipsarritmia no segundo EEG em 6 crianças (46 por cento), tendo 4 destas ficado livre dos espasmos. Nossos dados sugerem que a VGB é eficaz e bem tolerada como monoterapia inicial para a SW.

We evaluated the efficacy of vigabatrin (VGB) as a first drug to be used as monotherapy for West syndrome (WS), its side effects and correlations with the electroencephalogram (EEG). The sample consisted of 13 infants examined between October 2001 and September 2002 at IMIP ambulatory patientsÆ office or private clinic. Administration of vigabatrin was around 118 mg/kg/day. Suppression of spasms was obtained in 4 children (31 percent), partial control in 3 (23 percent), 5 of them did not present therapeutic response (38 percent) and just one (8 percent) got worse. On the two patients with tuberous sclerosis, one was seizure-free and in another there was partial control. Side effects happened in 8 children (62 percent) and consisted of irritability, insomnia, somnolence and agitation, and all of them have been well tolerated. The second EEG showed disappearance of hipsarrhythmia in 6 patients (46 percent). Four of these were seizure-free. We conclude that VGB is effective and well tolerated as initial monotherapy for WS.

Topiramate Monotherapy in Infantile Spasm

Infantile spasm is an age-related refractory epilepsy. Topiramate is a new anticonvulsant with multiple mechanisms of action, and it may be effective for treating pediatric epilepsies. To evaluate the efficacy and tolerability of first-line topiramate treatment for infantile spasm, 20 patients received topiramate monotherapy during this study. They were treated with an initial dose of 1mg/kg/day, with a progressive titration of 1 mg/kg a week until their spasms were controlled and a maximum dose of 12mg/kg/day was achieved. The evaluation of the treatment efficacy was based on the spasm frequency data that was obtained by the scalp and video-EEG, and by the parental count of spasm. Thirty percent of the subjects became spasm-free during the study. Six of 20 subjects (30%) had cessation of spasm and disappearance of hypsarrhythmia as seen via the video EEG; four (50%) of eight idiopathic patients had a response, whereas two (17%) of 12 patients with symptomatic infantile spasm responded. Seventy of the patients, including the spasm-free patients, had a reduction in their seizure frequency of more than 50%, and 10% of the patients had a reduction in their seizure frequency of less than 50%. The clusters of spasm frequency decreased from 10.6 +/- 8.5 to 3.5 +/- 1.4 clusters/day. Topiramate is effective and tolerated in those patients suffering from infantile spasm. Our results suggest that this drug should be considered as a new first-line drug for treating infantile spasm.

Avaliação da eficácia e tolerabilidade da vigabatrina na síndrome de West / Efficacy and tolerability of vigabatrin in West syndrome

A síndrome de West (SW) é uma epilepsia grave específica da infância, que se caracteriza pela tríade: espasmos em salvas, deterioração ou atraso neuropsicomotor e hipsarritmia ao eletrencefalograma. OBJETIVO: Avaliar a eficácia e segurança da vigabatrina (VGB) no tratamento da SW. MÉTODO: Foram sujeitos do estudo todos os pacientes com diagnóstico estabelecido de SW, que freqüentam ou freqüentaram o Ambulatório de Epilepsia Infantil do Hospital das Clínicas da UNICAMP, usam ou usaram VGB na tentativa de controlar as crises. Avaliamos sexo, idade, etiologia (sintomática ou criptogênica), doença(s) associada(s), idade do início dos espasmos, freqüência das crises antes e após o uso de VGB, achados de neuroimagem, EEG antes e depois do uso de VGB, medicações associadas, tempo para controle das crises, eletroretinograma, queixa visual após uso de VGB, efeitos adversos e história familial de epilepsia. RESULTADOS: Foram avaliados 23 pacientes, sendo 16 do sexo masculino. A idade variou entre 1ano e 3 meses a 11 anos e 5meses (média = 5anos e 3meses). Dezesseis (69,5 por cento) pacientes apresentaram controle completo das crises, 5 (22 por cento) tiveram controle parcial e em 2 (8,5 por cento) pacientes os espasmos não foram controlados. Apenas uma paciente teve retinopatia gabaérgica. Seis pacientes (26 por cento) apresentaram eventos adversos - sonolência, agressividade ou retinopatia. Os pacientes com o início da SW após 6 meses de idade apresentaram melhor resposta à VGB (p<0,05). Não houve diferença na resposta ao tratamento quanto ao tempo de introdução da VGB ou à etiologia (p>0,05). Após o tratamento com VGB, nenhum EEG apresentou hipsarritmia e 50 por cento normalizaram. CONCLUSÃO: Apesar do risco de retinopatia gabaérgica, os resultados acima mostram que o uso da VGB no controle dos espasmos infantis se justifica em pacientes com SW.

An Atypical Case of Aicardi Syndrome with Favorable Outcome

Aicardi syndrome is a severe congenital disorder characterized by infantile spasms, chorioretinal lacunae, and agenesis or hypogenesis of the corpus callosum. A 6 month old female had developed abnormal eye movement and seizures of the complex partial type and myoclonic type. MRI pictures of the patient revealed the presence of genu associated with agenesis of the rest of corpus callosum. A funduscopic examination revealed bilateral small, solitary, pale areas with sharp borders, some of which had minimal surrounding pigmentation (chorioretinal lacunae), especially clustered around the disc, and they were more prominent on the left side. We report here on the unusual findings of a complex partial seizure, myoclonic seizure and the atypical EEG finding in addition to the well-known characteristic clinical and imaging findings of a patient with Aicardi syndrome.

Vigabarina no tratamento da epilepsia de difícil controle em pacientes com síndrome de West e esclerose tuberosa / Vigabatrin in the treatment of epilepsy in patients with West syndrome and tuberous sclerosis

OBJETIVO: é relatar a eficácia da vigabatrina no controle das convulsões, bem como as alterações eletrencefalográficas em crianças com esclerose tuberosa e síndrome de West. MÉTODO: Estudo retrospectivo, com dados clínicos, de neuroimagem e de eletrencefalograma. RESULTADOS: Sete pacientes foram acompanhados e o tempo médio de seguimento foi 10 anos. Dos pacientes, quatro eram do sexo feminino e todos eram de cor branca. A média de idade de início das convulsões foi 3,4 meses. Todos usaram associações de vários anticonvulsivantes; no mínimo duas drogas por esquema terapêutico, e cada paciente utilizou pelo menos dois esquemas diferentes. O uso de vigabatrina como monoterapia ou em associação iniciou em média aos 7 anos de idade ou 4 anos após início dos sintomas. Cinco dos sete pacientes que iniciaram vigabatrina ficaram sem crise. CONCLUSÃO: Vigabatrina mostrou-se eficaz no controle das crises, levando a um melhor prognóstico

Síndrome de West: evoluçao clínica e eletrencefalográfica de 70 pacientes e resposta ao tratamento com hormônio adrenocorticotrófico, prednisona, vigabatrina, nitrazepam e ácido valpróico / West syndrome: clinical and eletroencephalographic follow up of 70 patients and response to the adrenocorticotropic hormone, prednisone, vigabatrin, nitrazepam and valproate

Em estudo retrospectivo avaliamos a evoluçao clínica e eletrencefalográfica das formas criptogênica e sintomática da síndrome de West e analisamos a eficácia do hormônio adrenocorticotrófico, vigabatrina, prednisona, ácido valpróico e nitrazepam no controle dos espasmos. Participaram do estudo 70 pacientes, acompanhados por período maior que 2 anos. Doze (17 por cento) eram criptogênicos e 58 (83 por cento) sintomáticos. O grupo criptogênico apresentou percentagem significativamente maior de pacientes que frequentavam escola regular e desenvolvimento motor normal, melhor controle das crises epilépticas, tendência menor a evoluir para síndrome de Lennox Gastaut e 83,3 por cento tiveram controle completo dos espasmos (72,4 por cento dos pacientes do grupo sintomático obtiveram controle completo dos espasmos). O hormônio adrenocorticotrófico e a vigabatrina foram as drogas mais eficazes, controlando 68,75 por cento e 60 por cento dos espasmos, respectivamente, quando utilizados como droga de primeira escolha e 75 por cento e 50 por cento, respectivamente, como drogas de segunda escolha

Espasmos infantis: experiência em treze casos / Infantile spasms: experience in 13 cases

Os espasmos infantis são crises típicas da primeira infância e constituem patologia grave, com prognóstico sombrio. Apresentamos a experiência no tratamento de 13 casos novos atendidos no Serviço de Neurologia Infantil do Centro Geral de Pediatria FHEMIG de Belo Horizonte no ano de 1997, bem como revisão da literatura sobre o assunto. Após propedêutica adequada encontramos 12 casos considerados sintomáticos e 1 criptogenético. Todos os casos foram tratados com ACTH durante 6 semanas, associado a drogas antiepilépticas orais de manutenção em mono ou politerapia. Os resultados com o ACTH foram excelentes num momento inicial, com resposta completa em todos os casos e efeitos colaterais que não contra-indicaram o tratamento. Porém houve índice de recorrência de 55 por cento, sendo usada como droga de segunda linha a vigabatrina em 5 casos, com controle de 4 deles. Todos os casos apresentaram atraso do desenvolvimento neuropsicomotor.

Vigabatrin in infantile spasms: preliminary result.

PURPOSE: To evaluate the efficacy of vigabatrin in the treatment of infantile spasms in Thai children. PATIENTS & METHOD: From March 1996 to May 1998, patients aged under 2 years presenting with infantile spasms at Ramathibodi Hospital were initiated with vigabatrin 35-50 mg/kg/day in two-divided doses. The dosage was escalated by 25 mg/kg weekly until spasms ceased or the maximum dose of 130 mg/kg was reached. RESULTS: There were 20 patients enrolled. The ages ranged from 3 to 23 months (mean 7.6 months). They were categorized as 4 cryptogenic and 16 symptomatic. Infantile spasms were completely controlled in 12 patients (60%). Six patients (30%) had at least 50 per cent reduction of seizure frequency. There were 2 patients whose seizure frequencies and severity were not altered. Only one patient whose infantile spasms partially responded to vigabatrin developed orofacial dyskinesis which disappeared after discontinuation of vigabatrin. Five patients had their vision evaluated which was unremarkable. Based on parental global evaluation, there was an increase in alertness, cheerfulness and interaction to the environment and stimulation in 8 out of 15 patients who were still taking vigabatrin and responded to treatment. CONCLUSION: Vigabatrin is effective for infantile spasms. A long-term follow-up of these patients is necessary to evaluate its efficacy and side-effects.